Table S3.
List of included studies with expert opinions and bibliographic information
| ID | Primary study citation |
|---|---|
| B1 | Weiss M, Jain U, Garland J. Clinical suggestions for management of stimulant treatment in adolescents. Can J Psychiatry. 2000;45(8):717–723. |
| B2 | Charach A, Fernandez R. Enhancing ADHD medication adherence: challenges and opportunities. Curr Psychiatry Rep. 2013;15(7):371. |
| B3 | Rothenberger A, Rothenberger LG. Updates on treatment of attention-deficit/hyperactivity disorder: facts, comments, and ethical considerations. Curr Treat Options Neurol. 2012;14(6):594–607. |
| B4 | Rothenberger A, Döpfner M. Editorial: Observational studies in ADHD: the effects of switching to modified-release methylphenidate preparations on clinical outcomes and adherence. Eur Child Adolesc Psychiatry. 2011;20 Suppl 2:S235–S242. |
| B5 | Brinkman WB, Epstein JN. Treatment planning for children with attention-deficit/hyperactivity disorder: treatment utilization and family preferences. Patient Prefer Adherence. 2011;5:45–56. |
| B6 | Graham J, Banaschewski T, Buitelaar J, et al; European Guidelines Group. European guidelines on managing adverse effects of medication for ADHD. Eur Child Adolesc Psychiatry. 2011;20(1):17–37. |
| B7 | Chacko A, Newcorn JH, Feirsen N, Uderman JZ. Improving medication adherence in chronic pediatric health conditions: a focus on ADHD in youth. Curr Pharm Des. 2010;16(22):2416–2423. |
| B8 | Rösler M, Casas M, Konofal E, Buitelaar J. Attention deficit hyperactivity disorder in adults. World J Biol Psychiatry. 2010;11(5):684–698. |
| B9 | Van der Westhuuizen A. Evidence-based pharmacy practice (EBPP): attention deficit hyperactivity disorder (ADHD). SA Pharmaceutical Journal. 2010;77(8):10–14,16, 18–20. |
| B10 | Buitelaar J, Medori R. Treating attention-deficit/hyperactivity disorder beyond symptom control alone in children and adolescents: a review of the potential benefits of long-acting stimulants. Eur Child Adolesc Psychiatry. 2010;19(4):325–340. |
| B11 | Dopheide JA. The role of pharmacotherapy and managed care pharmacy interventions in the treatment of ADHD. Am J Manag Care. 2009;15(5 Suppl):S141–S150. |
| B12 | Coury D. Dexmethylphenidate for attention deficit hyperactivity disorder. Expert Opin Pharmacother. 2009;10(16):2679–2685. |
| B13 | Graham L. AHA releases recommendations on cardiovascular monitoring and the use of ADHD medications in children with heart disease. Am Fam Physician. 2009;79(10):905–910. |
| B14 | Dopheide JA, Pliszka SR. Attention-deficit-hyperactivity disorder: an update. Pharmacotherapy. 2009;29(6):656–679. |
| B15 | Barkley RA. Global issues related to the impact of untreated attention-deficit/hyperactivity disorder from childhood to young adulthood. Postgrad Med. 2008;120(3):48–59. |
| B16 | Van Cleave J, Leslie LK. Approaching ADHD as a chronic condition: implications for long-term adherence. J Psychosoc Nurs Ment Health Serv. 2008;46(8):28–37. |
| B17 | Charach A, Gajaria A. Improving psychostimulant adherence in children with ADHD. Expert Rev Neurother. 2008;8(10):1563–1571. |
| B18 | Schlander M. Is NICE infallible? A qualitative study of its assessment of treatments for attention-deficit/hyperactivity disorder (ADHD). Curr Med Res Opin. 2008;24(2):515–535. |
| B19 | Weisler RH. Review of long-acting stimulants in the treatment of attention deficit hyperactivity disorder. Expert Opin Pharmacother. 2007;8(6):745–758. |
| B20 | Manos MJ, Tom-Revzon C, Bukstein OG, Crismon ML. Changes and challenges: managing ADHD in a fast-paced world. J Manag Care Pharm. 2007;13(9 Suppl B):S2–S13; quiz S14–S16. |
| B21 | López FA. ADHD: new pharmacological treatments on the horizon. J Dev Behav Pediatr. 2006;27(5):410–416. |
| B22 | Ashton H, Gallagher P, Moore B. The adult psychiatrist’s dilemma: psychostimulant use in attention deficit/hyperactivity disorder. J Psychopharmacol. 2006;20(5):602–610. |
| B23 | Wolraich ML, Wibbelsman CJ, Brown TE, et al. Attention-deficit/hyperactivity disorder among adolescents: a review of the diagnosis, treatment, and clinical implications. Pediatrics. 2005;115(6):1734–1746. |
| B24 | Dodson WW. Pharmacotherapy of adult ADHD. J Clin Psychol. 2005;61(5):589–606. |
| B25 | Staufer WB, Greydanus DE. Attention-deficit/hyperactivity disorder psychopharmacology for college students. Pediatr Clin North Am. 2005;52(1):71–84, viii. |
| B26 | Olfson M. New options in the pharmacological management of attention-deficit/hyperactivity disorder. Am J Manag Care. 2004;10(4 Suppl):S117–S124. |
| B27 | Greydanus DE, Pratt HD, Sloane MA, Rappley MD. Attention-deficit/hyperactivity disorder in children and adolescents: interventions for a complex costly clinical conundrum. Pediatr Clin North Am. 2003;50(5):1049–1092, vi. |
| B28 | Swanson J. Compliance with stimulants for attention-deficit/hyperactivity disorder: issues and approaches for improvement. CNS Drugs. 2003;17(2):117–131. |
| B29 | Bussing R, Gary FA. Practice guidelines and parental ADHD treatment evaluations: friends or foes? Harv Rev Psychiatry. 2001;9(5):223–233. |
| B30 | Smith BH, Waschbusch DA, Willoughby MT, Evans S. The efficacy, safety, and practicality of treatments for adolescents with attention-deficit/hyperactivity disorder (ADHD). Clin Child Fam Psychol Rev. 2000;3(4):243–267. |
| B31 | Stine JJ. Psychosocial and psychodynamic issues affecting noncompliance with psychostimulant treatment. J Child Adolesc Psychopharmacol. 1994;4(2):75–86. |
| B32 | Hodgkins P, Shaw M, Coghill D, Hechtman L. Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment options. Eur Child Adolesc Psychiatry. 2012;21(9):477–492. |
| B33 | Jensen CE. Medication for children with attention-deficit hyperactivity disorder. Clin Social Work J. 2004;32(2):197–214. |
| B34 | Garland EJ. Pharmacotherapy of adolescent attention deficit hyperactivity disorder: challenges, choices and caveats. J Psychopharmacol. 1998;12(4):385–395. |
| B35 | Greenhill LL, Pliszka S, Dulcan MK, et al. Summary of the practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry. 2001;40(11):1352–1355. |
| B36 | Pliszka S; AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(7):894–921. |